2025 Q4 -tulosraportti
UUTTA
7 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
33,29%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 982 | - | - | ||
| 1 | - | - | ||
| 1 870 | - | - | ||
| 3 000 | - | - | ||
| 557 | - | - |
Ylin
3,33VWAP
Alin
2,984VaihtoMäärä
5,2 1 619 000
VWAP
Ylin
3,33Alin
2,984VaihtoMäärä
5,2 1 619 000
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sitten🎯 Nykode: The run-up to Sevilla (March 20) – Bear, Base & Bull After weeks of "free fall," we now see signs of bottom formation around NOK 2.90–3.20. While the market has been characterized by fear, the clinical facts remain firm. Here's what we're looking for in Sevilla and what it means for the share price: 🛡️ The Foundation (Cash Floor): NOK 2.78 Before we look up, we must look down. Nykode currently has cash reserves of approx. NOK 1.78/share + a probable tax claim of NOK 1.00/share (answer expected 1H 2026). • Conclusion: At today's prices, the technology is valued at almost zero. 🐻 BEAR Case: "The Keytruda Flash" • Data: Short-lived responses (under 6 months), weak link between T-cells and tumor shrinkage. • Narrative: The market believes the results are due to luck or Keytruda alone. • Price Target: NOK 2.00 – 2.50 (Technology valued at zero, stock trades below cash value). ⚖️ BASE Case: "Solid, but Waiting" • Data: Confirmed 38.5 % ORR with stable duration. T-cell data shows the vaccine is working, but no "extreme" outcomes. • Narrative: De-risking of the platform, but the market will wait for Abili-T (2027) before full repricing. • Price Target: NOK 4.50 – 6.00 (Normalization to the levels before February's panic fall). 🚀 BULL Case: "The EyeBio-Moment" • Data: "Spider Plots" showing Durable Response (9+ months), TCR evidence for vaccine cells inside the tumor, and perhaps a conversion from PR to CR (tumor completely gone). • Narrative: Nykode doubles the effect of standard treatment. The comparison with Merck's acquisition of EyeBio ($1.3 billion upfront for early-stage data) becomes impossible to ignore. • Price Target: NOK 12.00 – 18.00 (The market begins to price in a real acquisition probability). 🔍 What should we look for on the slides? 1. Spider Plots: Look for flat lines below the -30 % threshold. Duration is everything! 2. TCR-graphs: Evidence that the vaccine T-cells actually find their way into the tumor. 3. Ongoing Responses: Small arrows at the end of the graphs, meaning the patient is still alive and responding. Summary: On March 20 at 15:15 in Sevilla, we will get the answer whether the technology is worth 13 øre or 60 kroner. With a downside that is practically covered by cash, the risk/reward ratio is unique. Thoughts? Anything else we should look for or that hasn't been considered?
·4 t sittenAnyone starting to realize that the stock is dirt cheap? About time.
·23 t sitten · MuokattuCan there be a bid for the company!? Of course, but what is the probability? 📍Time aspect; well, by the end of the year 📍Price; 10ish probably makes the major shareholders move 📍More players entering the field? Well 📍The company is tired of Norway and the stock exchange here, I think they would gladly see a listing and fresh start elsewhere. 📍Am I speculating? YES 📍Am I long? YES·6 t sittenI like champagne a bit colder than average. Perhaps one standard deviation from the norm, and go for 12-12,5 degrees. No point in going vintage with Krug, grand cuve does the job no matter what price the bid comes in at.- ·1 päivä sittenTime for a FOMO rally here. Personally, I interpret the undertones in the messages from the company that this will be mega big. Others may interpret as they wish.·23 t sittenUtter FOMO, you know, and especially when the price goes above 4,00 again. Loaded up a bit more. And to that knob who started talking about positive CF and not losing money in here (Vincent). Sorry, man, but I read all threads or whatever it's called (replies maybe). Spare me...
·1 päivä sitten
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
7 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
33,29%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sitten🎯 Nykode: The run-up to Sevilla (March 20) – Bear, Base & Bull After weeks of "free fall," we now see signs of bottom formation around NOK 2.90–3.20. While the market has been characterized by fear, the clinical facts remain firm. Here's what we're looking for in Sevilla and what it means for the share price: 🛡️ The Foundation (Cash Floor): NOK 2.78 Before we look up, we must look down. Nykode currently has cash reserves of approx. NOK 1.78/share + a probable tax claim of NOK 1.00/share (answer expected 1H 2026). • Conclusion: At today's prices, the technology is valued at almost zero. 🐻 BEAR Case: "The Keytruda Flash" • Data: Short-lived responses (under 6 months), weak link between T-cells and tumor shrinkage. • Narrative: The market believes the results are due to luck or Keytruda alone. • Price Target: NOK 2.00 – 2.50 (Technology valued at zero, stock trades below cash value). ⚖️ BASE Case: "Solid, but Waiting" • Data: Confirmed 38.5 % ORR with stable duration. T-cell data shows the vaccine is working, but no "extreme" outcomes. • Narrative: De-risking of the platform, but the market will wait for Abili-T (2027) before full repricing. • Price Target: NOK 4.50 – 6.00 (Normalization to the levels before February's panic fall). 🚀 BULL Case: "The EyeBio-Moment" • Data: "Spider Plots" showing Durable Response (9+ months), TCR evidence for vaccine cells inside the tumor, and perhaps a conversion from PR to CR (tumor completely gone). • Narrative: Nykode doubles the effect of standard treatment. The comparison with Merck's acquisition of EyeBio ($1.3 billion upfront for early-stage data) becomes impossible to ignore. • Price Target: NOK 12.00 – 18.00 (The market begins to price in a real acquisition probability). 🔍 What should we look for on the slides? 1. Spider Plots: Look for flat lines below the -30 % threshold. Duration is everything! 2. TCR-graphs: Evidence that the vaccine T-cells actually find their way into the tumor. 3. Ongoing Responses: Small arrows at the end of the graphs, meaning the patient is still alive and responding. Summary: On March 20 at 15:15 in Sevilla, we will get the answer whether the technology is worth 13 øre or 60 kroner. With a downside that is practically covered by cash, the risk/reward ratio is unique. Thoughts? Anything else we should look for or that hasn't been considered?
- ·4 t sittenAnyone starting to realize that the stock is dirt cheap? About time.
- ·23 t sitten · MuokattuCan there be a bid for the company!? Of course, but what is the probability? 📍Time aspect; well, by the end of the year 📍Price; 10ish probably makes the major shareholders move 📍More players entering the field? Well 📍The company is tired of Norway and the stock exchange here, I think they would gladly see a listing and fresh start elsewhere. 📍Am I speculating? YES 📍Am I long? YES·6 t sittenI like champagne a bit colder than average. Perhaps one standard deviation from the norm, and go for 12-12,5 degrees. No point in going vintage with Krug, grand cuve does the job no matter what price the bid comes in at.
- ·1 päivä sittenTime for a FOMO rally here. Personally, I interpret the undertones in the messages from the company that this will be mega big. Others may interpret as they wish.·23 t sittenUtter FOMO, you know, and especially when the price goes above 4,00 again. Loaded up a bit more. And to that knob who started talking about positive CF and not losing money in here (Vincent). Sorry, man, but I read all threads or whatever it's called (replies maybe). Spare me...
- ·1 päivä sitten
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 982 | - | - | ||
| 1 | - | - | ||
| 1 870 | - | - | ||
| 3 000 | - | - | ||
| 557 | - | - |
Ylin
3,33VWAP
Alin
2,984VaihtoMäärä
5,2 1 619 000
VWAP
Ylin
3,33Alin
2,984VaihtoMäärä
5,2 1 619 000
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
2025 Q4 -tulosraportti
UUTTA
7 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
1,00 NOK/osake
Viimeisin osinko
33,29%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sitten🎯 Nykode: The run-up to Sevilla (March 20) – Bear, Base & Bull After weeks of "free fall," we now see signs of bottom formation around NOK 2.90–3.20. While the market has been characterized by fear, the clinical facts remain firm. Here's what we're looking for in Sevilla and what it means for the share price: 🛡️ The Foundation (Cash Floor): NOK 2.78 Before we look up, we must look down. Nykode currently has cash reserves of approx. NOK 1.78/share + a probable tax claim of NOK 1.00/share (answer expected 1H 2026). • Conclusion: At today's prices, the technology is valued at almost zero. 🐻 BEAR Case: "The Keytruda Flash" • Data: Short-lived responses (under 6 months), weak link between T-cells and tumor shrinkage. • Narrative: The market believes the results are due to luck or Keytruda alone. • Price Target: NOK 2.00 – 2.50 (Technology valued at zero, stock trades below cash value). ⚖️ BASE Case: "Solid, but Waiting" • Data: Confirmed 38.5 % ORR with stable duration. T-cell data shows the vaccine is working, but no "extreme" outcomes. • Narrative: De-risking of the platform, but the market will wait for Abili-T (2027) before full repricing. • Price Target: NOK 4.50 – 6.00 (Normalization to the levels before February's panic fall). 🚀 BULL Case: "The EyeBio-Moment" • Data: "Spider Plots" showing Durable Response (9+ months), TCR evidence for vaccine cells inside the tumor, and perhaps a conversion from PR to CR (tumor completely gone). • Narrative: Nykode doubles the effect of standard treatment. The comparison with Merck's acquisition of EyeBio ($1.3 billion upfront for early-stage data) becomes impossible to ignore. • Price Target: NOK 12.00 – 18.00 (The market begins to price in a real acquisition probability). 🔍 What should we look for on the slides? 1. Spider Plots: Look for flat lines below the -30 % threshold. Duration is everything! 2. TCR-graphs: Evidence that the vaccine T-cells actually find their way into the tumor. 3. Ongoing Responses: Small arrows at the end of the graphs, meaning the patient is still alive and responding. Summary: On March 20 at 15:15 in Sevilla, we will get the answer whether the technology is worth 13 øre or 60 kroner. With a downside that is practically covered by cash, the risk/reward ratio is unique. Thoughts? Anything else we should look for or that hasn't been considered?
- ·4 t sittenAnyone starting to realize that the stock is dirt cheap? About time.
- ·23 t sitten · MuokattuCan there be a bid for the company!? Of course, but what is the probability? 📍Time aspect; well, by the end of the year 📍Price; 10ish probably makes the major shareholders move 📍More players entering the field? Well 📍The company is tired of Norway and the stock exchange here, I think they would gladly see a listing and fresh start elsewhere. 📍Am I speculating? YES 📍Am I long? YES·6 t sittenI like champagne a bit colder than average. Perhaps one standard deviation from the norm, and go for 12-12,5 degrees. No point in going vintage with Krug, grand cuve does the job no matter what price the bid comes in at.
- ·1 päivä sittenTime for a FOMO rally here. Personally, I interpret the undertones in the messages from the company that this will be mega big. Others may interpret as they wish.·23 t sittenUtter FOMO, you know, and especially when the price goes above 4,00 again. Loaded up a bit more. And to that knob who started talking about positive CF and not losing money in here (Vincent). Sorry, man, but I read all threads or whatever it's called (replies maybe). Spare me...
- ·1 päivä sitten
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 982 | - | - | ||
| 1 | - | - | ||
| 1 870 | - | - | ||
| 3 000 | - | - | ||
| 557 | - | - |
Ylin
3,33VWAP
Alin
2,984VaihtoMäärä
5,2 1 619 000
VWAP
Ylin
3,33Alin
2,984VaihtoMäärä
5,2 1 619 000
Välittäjätilasto
Dataa ei löytynyt